Radotinib Y10505 a linker and an VHL

a linker and an VHL binding group

19(11):967-980

APN and cysteine-conjugated-β-lyase (CCBL) nephrotoxigenic pathway are proposed which acting in a concerted and/or synergistic manner

Chemical Name: ((2

Radotinib Y10505 a linker and an VHLRadotinib, also known as IY 5511, is an orally available, a second generation tyrosine kinase inhibitor of Bcr Abl fusion protein and the platelet derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR